$179 Million is the total value of Essex Woodlands Management, Inc.'s 7 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDXG | MIMEDX GROUP, INC. | $65,095,324 | -3.1% | 23,415,584 | 0.0% | 36.30% | +30.7% | |
| TELA | TELA BIO, INC. | $47,273,154 | +35.0% | 4,110,709 | 0.0% | 26.36% | +82.1% | |
| BVS | BIOVENTUS | $31,572,392 | -62.7% | 12,096,702 | 0.0% | 17.60% | -49.7% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $14,668,224 | -55.8% | 4,190,921 | 0.0% | 8.18% | -40.3% | |
| VERO | Buy | VENUS CONCEPT, INC. | $10,028,114 | +39.5% | 31,337,856 | +48.0% | 5.59% | +88.2% |
| RVNC | REVANCE THERAPEUTICS INC | $8,437,789 | -31.6% | 457,085 | 0.0% | 4.70% | -7.7% | |
| MNOV | MEDICINOVA INC | $2,267,179 | -5.5% | 1,105,941 | 0.0% | 1.26% | +27.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDICINOVA INC | 42 | Q3 2023 | 6.5% |
| REVANCE THERAPEUTICS INC | 39 | Q3 2023 | 44.6% |
| AXOGEN INC | 26 | Q4 2021 | 43.3% |
| ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
| ABIOMED INC | 20 | Q1 2018 | 52.1% |
| CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
| TELA BIO, INC. | 16 | Q3 2023 | 31.5% |
| VENUS CONCEPT, INC. | 16 | Q3 2023 | 21.3% |
| ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
| CATALYST BIOSCIENCES INC | 15 | Q1 2019 | 1.0% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.